You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Combretastatin

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Combretastatin?

Combretastatin is an investigational drug.

There have been 19 clinical trials for Combretastatin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.

The most common disease conditions in clinical trials are Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, and Thyroid Diseases. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.

There are two US patents protecting this investigational drug and fifteen international patents.

Recent Clinical Trials for Combretastatin
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian CancerMateon TherapeuticsPhase 2/Phase 3
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDSMateon TherapeuticsPhase 1/Phase 2
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid CancerMateon TherapeuticsPhase 3

See all Combretastatin clinical trials

Clinical Trial Summary for Combretastatin

Top disease conditions for Combretastatin
Top clinical trial sponsors for Combretastatin

See all Combretastatin clinical trials

US Patents for Combretastatin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Combretastatin   Start Trial Anti-FGFR3 antibodies and methods using same Genentech, Inc. (South San Francisco, CA)   Start Trial
Combretastatin   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Combretastatin   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.